High Mobility Group Box 1 Expression in Wilms Tumor: Stage-stratified Survival Analysis in 46 Cases Wilms Tümöründe High Mobility Grup Box 1 Ekspresyonu: 46 Olguda Evreye Göre Tabakalandırılmış Sağkalım Analizi

Creative Commons License

Diniz G., AKTAŞ S., Ortaç R.

Journal of Behcet Uz Children's Hospital, cilt.16, sa.2, ss.120-126, 2026 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 2
  • Basım Tarihi: 2026
  • Doi Numarası: 10.4274/jbuch.galenos.2026.25826
  • Dergi Adı: Journal of Behcet Uz Children's Hospital
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.120-126
  • Anahtar Kelimeler: HMGB1, immunohistochemistry, nephroblastoma, overall survival, prognosis, stage-stratified analysis, Wilms tumor
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: To investigate High Mobility Group Box 1 (HMGB1) expression in Wilms tumors and determine its relationship with clinicopathological factors and overall survival (OS), including stage-stratified survival analyses. Method: Forty-six Wilms tumor cases were retrospectively evaluated. Immunohistochemical expression of HMGB1 was recorded as the percentage of HMGB1-positive tumor cells. Associations with clinicopathological parameters were tested using chi-square/Fisher’s exact and non-parametric tests. OS was assessed with Kaplan-Meier analysis and log-rank testing. Exploratory analyses included HMGB1 tertiles and a simplified “HMGB1-low” vs. “HMGB1-other” grouping. Stage was analyzed as low stage (1-2) vs. high stage (3-5). Results: HMGB1 dichotomized using 5% and 10% cut-offs showed no significant associations with clinicopathological variables or OS (p-value>0.05). Stage 3-5 cases had significantly worse OS compared with stage 1-2 (log-rank p-value=0.049). In stage 1-2 tumors, very low HMGB1 expression (1-4%) was associated with significantly worse OS compared with HMGB1expression of ≥5% (log-rank p-value=0.024). This association was not observed in stage 3-5 tumors (log-rank p=0.858). Conclusion: In this study, HMGB1 expression was not an independent prognostic marker in the overall cohort. However, very low HMGB1 expression may identify a subgroup of early-stage Wilms tumor patients with unfavorable survival and deserves validation in larger-scale studies.